InvestorsHub Logo
Followers 102
Posts 29139
Boards Moderated 3
Alias Born 09/17/2006

Re: nsomniyak post# 1474

Monday, 11/22/2010 9:46:21 PM

Monday, November 22, 2010 9:46:21 PM

Post# of 10951
A repeat post from after last Decembers shareholder meeting, I talked to two who were there and heard similar, but there could very well be some BS in this>>>>

I was told by people who were at the shareholder meeting themselves that there were peopel there from the Pharma side of the equation. They were told the upside here is beyond tremendous. From what I have learned some of the trials have been done, but BE decided to lavishly furnish a office building instead of paying for the trials. This is money that is owed so we can get the results. I don't know what the exact amount is, but I believe it to be in the six figures. I believe getting this and further info. on this front is a priority on Short's list. I know there is ton of interest in NYC from companies and institutions alike on this front alone.
Some of this has to do with Pharma drugs coming off patent exclusivity. If these companies can tweak their receipe by adding a NTRZ ingredient that changes the formula so to speak they can extend their exclusivity before it goes to generic. This is worth billions to them. I am not a biotech guy so don't quote me on this, but I know enough and I know who is looking. If Ntrz can prove to the world that they can add value on this front it's worth a TON of money to the bottom line. There are many potential applications and avenues to explore within this realm so it should be interesting. I know it is something that BE talked about, but never did anything with. Short,is doing something about it.

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_N/threadview?m=tm&bn=47300&tid=164729&mid=164763&tof=-1&rt=1&frt=2&off=1
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RIBT News